EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FDA first to global follow-on: alignment in expedited oncology approvals across EMA, TGA, and PMDA

Yehhyun Kim, Hisashi Urushihara, Gyeyoung Choi, Seungjin Bae

Frontiers in Pharmacology · 29.05.2026 · 17

DOI: 10.3389/fphar.2026.1804782 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.05.2026. Verfasst von Yehhyun Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Food and Drug Safety.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Oncology drugs often receive their first expedited approval in the United States, yet the degree of alignment with subsequent regulatory decisions in other jurisdictions remains uncertain. We examined concordance in evidentiary evaluation and review timelines between the US Food and Drug Administration (FDA)-first expedited oncology approvals and subsequent decisions by the European Medicines Agency (EMA), Therapeutic Goods Administration (TGA), and Pharmaceuticals and Medical Devices Agency (PMDA).

Methods

This study included all oncology drugs that received their first expedited approval from the FDA in 2019–2023. Subsequent EMA, TGA, and PMDA decisions were evaluated in pairwise comparison with the FDA. Concordance with the FDA was assessed for expedited pathway use, pivotal trial selection, and three analytical components (primary endpoint, target population, and data cut-off date (DCO)). Submission interval and review duration relative to the FDA were compared using Wilcoxon rank-sum tests.

Results

Among 36 FDA expedited oncology approvals, EMA (n = 28), TGA (n = 18), and PMDA (n = 15) granted subsequent authorizations through expedited or standard pathways. TGA showed the highest concordance with the FDA, retaining expedited pathways in 72% of cases and closely mirroring the FDA’s analytical interpretations in the same pivotal trials. EMA maintained a similar rate of expedited use (71%) but often broadened target populations or used later DCOs (median +136 days). PMDA, in contrast, relied mainly on standard approvals (93%) with Japan-specific population analyses. Across all agencies, primary endpoint choice remained concordant with the FDA. EMA had the shortest submission lag (median 27 days), whereas TGA cases exceeded 600 days. All agencies had longer review duration than the FDA.

Discussion

These findings highlight the need for international harmonization of regulatory frameworks and evidentiary thresholds to promote consistency in approval decisions and accelerate global access to innovative cancer therapies.

Schlagwörter

Stichwörter der Autor:innen

evidentiary maturityexpedited approval pathwaysoncology approvalsregulatory comparisonregulatory concordance

Autor:innen und Institutionen

  • College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea.
  • Division of Drug Development and Regulatory Science, Faculty of Pharmacy, Keio University, Tokyo, Japan.

Förderung

  • Ministry of Food and Drug Safety

Zitieren

APA

Kim, Y., Urushihara, H., Choi, G., & Bae, S. (2026). FDA first to global follow-on: alignment in expedited oncology approvals across EMA, TGA, and PMDA. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1804782

Vancouver

Kim Y, Urushihara H, Choi G, Bae S. FDA first to global follow-on: alignment in expedited oncology approvals across EMA, TGA, and PMDA. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1804782

BibTeX
@article{Kim2026,
  author = {Kim, Yehhyun and Urushihara, Hisashi and Choi, Gyeyoung and Bae, Seungjin},
  title = {FDA first to global follow-on: alignment in expedited oncology approvals across EMA, TGA, and PMDA},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1804782}
}
Kostenlos starten →